Hacer Durmuş

A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis

Paraskevi Zisimopoulou, Panagiota Evangelakou, John Tzartos et al. · Journal of Autoimmunity · 2013 · 324 citations · Full text

Life Sciences, Endocrinology, Immunology +11

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness

Ana Töpf, Katherine Johnson, Adam Bates et al. · Genetics in Medicine · 2020 · 108 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

CD4+ T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS

Merve Çebi, Hacer Durmuş, Fikret Aysal et al. · Frontiers in Immunology · 2020 · 93 citations · Full text

Life Sciences, Immunology, Pathology +17

Oculopharyngodistal myopathy is a distinct entity

Hacer Durmuş, Steven H. Laval, Feza Deymeer et al. · Neurology · 2011 · 86 citations

Medicine, Genetics, Neurology +13